Preclinical | Department of Molecular Pharmacology |

Departments

Academic Programs

Phone Book

Faculty Services

American Program

Photo Gallery

Forms

Contact Us

	Home	>	Preclinical	>	Department of Molecular Pharmacology	>	Academic Staff

Department of Molecular Pharmacology

Professor Emeritus Moussa Youdim

Main Research Area

	Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Teaching is an independent extension of the Department of Pharmacology at Technion-Rappaport Faculty of Medicine and has a close interaction with Rappaport Family Research Institute. It is dedicated in advancing the understanding of neuropsychiatric disorders, specially, neurodegenerative diseases. The centers main focus is to elucidate why and how neurons degenerate, employing cellular and animal models and to develop novel drugs to prevent or rescue them. This is accomplished by implementation of conventional and novel biochemical techniques combined with chemistry molecular biology, genomics and proteomics. This has led to identification and development of several novel neuroprotective anti-Parkinson and anti-Alzheimer drugs including rasagiline, TV3326 and (-)-epigallocatechin-3-gallate (EGCG). The Centers have close relationships and collaborations with Teva Pharmaceutical Co. (Israel) and a number of major institutes in Israel and abroad. Together with the Technion, Eve Topf Center is co-founder of Varinel Inc. (USA) which has developed novel brain permeable neuroprotective bifunctional iron chelators-monoamine oxidase (MAO) inhibitors for the treatment of neurodegenerative and systemic diseases, where misregulation of iron metabolism is implicated.

Journal articles

Click here for a list of available publications in PubMed.

Graduate students

	Lydia Reznichenko
	Studies towards Ph.D. Email: lydiarez@tx.technion.ac.il
	Neurorescue properties of the green tea polyphenol (-)-epigalloctechin-3-gallate (EGCG) in cell culture and animal models of Parkinson''s Disease, alone and in cocktail with neuroprotective drugs.



	Yael Chertkow
	Studies towards Ph.D. Email: cher@tx.technion.ac.il
	The effects of typical and atypical antipsychotics alone and in combination with '+chr(39)+'SSRI antidepressant on gene and protein expression and their relationship to clinical efficacy in schizophrenia.



	Yotam Sagi
	Studies towards Ph.D. Email: yotis@tx.technion.ac.il
	Pharmacological and molecular mechanisms of neuroprotectorals anti-Alzheimer and anti-Parkinson''s drugs TV3326, TV3279 and rasagiline.



	Limor Kalfon-Tal
	Studies towards Ph.D. Email: tlimor@techunix.technion.ac.il
	Molecular Mechanisms and Signaling Pathways Mediating the Neuroprotective Action of the Green Tea Polyphenol, (-)-Epigallocatechin 3-Gallate (EGCG)



	Merav Yogev-Falach
	Studies towards Ph.D. Email: yagel@tx.technion.ac.il
	Amyloid precursor protein processing and neuroprotection by the '+chr(39)+'anti-alzheimer''s drug, Ladostigil (TV3326)



	Noam Drigues
	Studies towards MD-Ph.D. Email: drigues@tx.technion.ac.il
	Gene Expression Profile in Rat Hippocampus After Chronic Administration of Antidepressant Drugs.



	Shunit Ben-Ari (Gal)
	Studies towards Ph.D. Email: gshunit@tx.technion.ac.il
	Novel multifunctional beuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases.



	Yael Avramovich-Tirosh
	Studies towards Ph.D. Email: yaelomer@yahoo.com
	Neurorescue mechanisms and processing of the Alzheimer''s disease APP by novel multi- functional iron- chelator drugs.



	Merav Oren
	Studies towards M.Sc. Email: mer@tx.technion.ac.il
	\"Neuroprotection by novel iron chelator in the kainic acid model of neurodegeneration \"



	Ayelet Blank
	Studies towards M.Sc. Email: blanka@tx.technion.ac.il


	Back	Top page